Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5172-5179
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Table 4 Comparison of survival and progression-free survival between the two groups
| Follow-up results | S-1 group (n = 47) | Gemcitabine group (n = 47) | t | P value |
| Progress-free survival (mo) | 6.63 (1.02) | 6.25 (0.94) | 1.878 | 0.064 |
| Survival (mo) | 13.63 (1.52) | 13.02 (1.45) | 1.991 | 0.050 |
- Citation: Cheng XW, Leng WH, Mu CL. Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients. World J Clin Cases 2020; 8(21): 5172-5179
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5172.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5172